Dexpramipexole-d3 dihydrochloride

Modify Date: 2024-01-13 19:36:45

Dexpramipexole-d3 dihydrochloride structure	Common Name	Dexpramipexole-d3 dihydrochloride
	CAS Number	1432230-09-5	Molecular Weight	287.27
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₀H₁₆D₃Cl₂N₃S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Dexpramipexole-d3 dihydrochloride

Dexpramipexole-d3 ((R)-Pramipexole-d3) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole((R)-Pramipexole), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist[1][2].

Name	Dexpramipexole-d3 dihydrochloride

Description	Dexpramipexole-d3 ((R)-Pramipexole-d3) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole((R)-Pramipexole), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler [3]. Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11. [4]. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6. [5]. Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011 Aug;51(8):1177-85. [6]. Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13(12):911-20.

Molecular Formula	C₁₀H₁₆D₃Cl₂N₃S
Molecular Weight	287.27

Dexpramipexole-d3 dihydrochloride

Use of Dexpramipexole-d3 dihydrochloride

Names

Dexpramipexole-d3 dihydrochloride Biological Activity

Chemical & Physical Properties